Aqsens Health Oy and The New Children’s Hospital and University of Helsinki have conducted comprehensive research tests to improve the diagnostics and care of inflammatory bowel disease (IBD). They have applied a novel affordable method that will complement the existing screening methods by offering opportunities to classify IBD subtypes (Crohn’s disease and ulcerative colitis) and further to measure treatment responses. The tests have been validated at VTT Technical Research Centre of Finland Ltd..
After several months of research and confirming complementary tests, the parties are now revealing their first results of their collaborative work. Based on the audited results, a novel mechanism as a signature of oxidative stress is detectable in fecal samples of the patients with IBD. This measurement provides means to stratify patients with IBD from non-IBD patients. This finding and the respective new test called AQ IBDⓇ will complement the existing fecal calprotectin tests and improve diagnostics and treatment plans being affordable. During the 1Q 2020 the parties will publish comprehensive data on the findings and furthermore, a scientific publication on the results is under the preparation.
“With these results the IBD research has taken a step forward. Getting a novel complementary test into use will help healthcare professionals to diagnose their patients more accurately and to find the right treatment plans faster, which will ultimately lead into improved care”, says Kaija-Leena Kolho, Professor of Pediatrics at University of Helsinki. This will form a good foundation for future development work.
“Having such groundbreaking results after seven months’ work underlines the capabilities of our patented E-TRF method. Its sensitivity and agility provide tools to develop different kinds of non-invasive health screening applications and AQ IBDⓇ will be the first one we will bring into the market. Essential part of the method is the collaborative working process with the clinical researchers – without their guidance we would have not reached our goals”, says the CEO of Aqsens Health, Timo Teimonen.
“In autumn 2019 we conducted independent 3rd party analysis for Aqsens Health Oy’s IBD measurement results of the blinded fecal samples. We were surprised by the exceptionally high specificity with a sensitivity over 90%, and we also found out E-TRF as a very intriguing method.”, says Mark van Gils, Research Professor, AI in Wellness and Healthcare at VTT
The parties will continue their work to classify IBD and on how treatment responses can be measured. They will also experiment testing of IBD from other body fluids, like saliva and urine. The ultimate goal is to develop and deliver comprehensive toolset to support healthcare professionals’ work on providing better service for their patients.
Timo Teimonen, CEO of Aqsens Health Oy, tel. +358 40 585 3105
Kaija-Leena Kolho, Professor of Pediatrics, Helsinki University, tel +358 50 427 4858
Mark van Gills, Research Professor AI in Wellness and Healthcare at VTT, +358 20 722 3342
About Aqsens Health:
Aqsens Health has developed and patented a non-invasive screening and diagnosis method E-TRF (Enhanced Time-Resolved Fluorescence) to analyze urine, saliva and feces. With the use of machine learning and other big data analysis algorithms, it can detect exceptionally small-scale metabolic signatures, i.e. early stage disease indicators from the human body fluids. The company’s focus is on non-invasive screening of health disorders having major impact for both individual patients and society.